LXRX
Lexicon Pharmaceuticals, Inc. Health Care Pharmaceutical Preparations Russell 3000
$1.42Close
$519.5MMarket cap
$1.14 – $2.6452-week range
Nov 5, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 2 of 8 trend conditions
- Lagging the market RS 23 · weaker than 77% of stocks over 12 months
- Far from its high 46% below its 52-week high
- Earnings shrinking EPS −912% year on year
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
46%
1wk
0.0%
price change
1mo
down 24.5%
price change
12-month return
up 6%
market up 11% ·
its own down 4%
F-score
4 / 9
Weak
Altman Z
-11.32
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.8×
price / book
Earnings yield
down 9.1%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 730%
year on year
EPS growth
down 912%
latest quarter
Sales growth
—
latest quarter
ROE
down 40%
return on equity
Free cash margin
down 136%
-$67.9M FCF
D/E
0.46
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profits not fully backed by cash
- short-term liquidity weakened
- issued more shares
- profitability improving
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- Long-term debt down 51% ($0.1B → $0.0B)
- Gross margin 89.7% → 99.4%
Trade setup
ATR%
6.7%
$0.09 a day · 2×ATR $1.23
RS
23 / 99
vs the universe
Trend
2 / 8
trend template
Relative volume
0.9×
vs 50-day average
Up/down volume
0.82
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 2 of 8
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 20260% vs market2 sessions after results
Financials
- Gross 99%
- Net -101%
- Free cash -136%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $23.4M | $0 | $0 | $1.1M | $6.0M | $49.8M |
| Gross margin | 92% | — | — | 92% | 90% | 99% |
| Operating income | -$47.8M | -$87.1M | -$100.8M | -$171.8M | -$197.1M | -$48.9M |
| Net income | -$58.6M | -$87.8M | -$101.9M | -$177.1M | -$200.4M | -$50.3M |
| Net margin | -250% | — | — | -15957% | -3339% | -101% |
| Earnings per share | -$0.53 | -$0.60 | -$0.62 | -$0.80 | -$0.63 | -$0.14 |
| Free cash flow | -$143.1M | -$88.2M | -$90.2M | -$162.4M | -$179.8M | -$67.9M |
| Free cash margin | -611% | — | — | -14628% | -2996% | -136% |
| Cash | $126.3M | $64.1M | $46.3M | $22.5M | $66.7M | $34.3M |
| Long-term debt | $0 | $0 | $48.6M | $99.5M | $100.3M | $49.4M |
| Shareholders' equity | $156.4M | $113.6M | $117.1M | $93.1M | $145.9M | $107.5M |
| Shares outstanding | 142.29m | 150.08m | 189.21m | 245.79m | 363.02m | 365.85m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Mar 5, 2026 | Annual ↗ | Dec 31, 2025 | 64d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 7, 2025 | Annual ↗ | Dec 31, 2024 | 66d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Mar 25, 2024 | Annual ↗ | Dec 31, 2023 | 85d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| May 7, 2026 | Results ↗ |
| May 6, 2026 | Material agreement · New obligation · Unregistered share sale · Regulation FD ↗ |
| Apr 30, 2026 | Material agreement · Unregistered share sale · Charter or bylaws · Shareholder vote ↗ |
| Mar 5, 2026 | Results ↗ |
| Feb 2, 2026 | Material agreement · Unregistered share sale · Holder rights changed · Charter or bylaws · Regulation FD ↗ |
| Jan 29, 2026 | Results · Regulation FD · Other events ↗ |
| Nov 10, 2025 | Other events ↗ |
| Nov 6, 2025 | Other events ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Jul 28, 2025 | Other events ↗ |